Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET

• On Track to Initiate Phase 1b Study of EDP-514 in Viremic Hepatitis B Patients in 2Q 2020 and Phase 1 Study of EDP-297 in 3Q 2020
• Royalty Revenue for the Quarter was $27.6 Million
• Cash and Marketable Securities Totaled $435.4 Million at March 31, 2020

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2020.

“Enanta is fortunate to have advanced several of its programs in the recent quarter and it continues to have a strong balance sheet and ongoing royalty funding to support its business plans going forward,” said Jay R. Luly, President and Chief Executive Officer of Enanta Pharmaceuticals. “The current pandemic has underscored our commitment as a company to bring forth novel anti-viral therapies for respiratory viruses and liver infections, and we remain highly dedicated to the clinical advancement of our innovative small molecule pipeline. We are on schedule to initiate our Phase 1b study of EDP-514 in viremic hepatitis B patients this quarter, and we also expect to initiate a first-in-human study of our follow-on Farnesoid X receptor agonist, EDP-297, next quarter. Additionally, we have plans for two additional studies of EDP-938 for respiratory syncytial virus to start by year-end, one in pediatric patients and one in adult transplant patients. With these catalysts in mind, we continue to monitor any impact of COVID-19 on all of our clinical studies.”

Fiscal Second Quarter Ended March 31, 2020 Financial Results

Total revenue for the three months ended March 31, 2020 was $27.6 million and consisted of royalty revenue derived primarily from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir). For the three months ended March 31, 2019, total revenue was $39.6 million, which consisted of royalty revenue earned on AbbVie’s global net sales of its HCV regimens. AbbVie has reported that the decrease in its first quarter 2020 HCV sales was due to lower patient volumes in select international markets where patients are treated in hospitals affected by COVID-19, as well as increased competition affecting pricing and market share within the U.S. Managed Medicaid segment.

Research and development expenses totaled $32.6 million for the three months ended March 31, 2020, compared to $34.2 million for the three months ended March 31, 2019. The decrease in research and development expenses was primarily due to a decrease in clinical trial expense due to timing of Phase 2 studies in non-alcoholic steatohepatitis (NASH)/primary biliary cholangitis (PBC) conducted in the prior year.

General and administrative expenses totaled $6.9 million for the three months ended March 31, 2020, compared to $6.8 million for the three months ended March 31, 2019.

Enanta recorded an income tax benefit of $3.9 million for the three months ended March 31, 2020 compared to an income tax benefit of $3.2 million for the same period of 2019. The income tax benefit for the three months ended March 31, 2020 was due to a pre-tax loss and increased research and development tax credits. In the prior year, Enanta recorded an income tax benefit despite reporting pre-tax income due to tax deductions from employee stock award-related activity during the quarter.

Net loss for the three months ended March 31, 2020 was $6.0 million, or a loss of $0.30 per diluted common share, compared to net income of $4.1 million, or $0.20 per diluted common share, for the corresponding period in 2019.

Enanta’s cash, cash equivalents and short-term and long-term marketable securities totaled $435.4 million at March 31, 2020. This compares to a total of $400.3 million at September 30, 2019. Enanta expects that its current cash, cash equivalents and marketable securities, as well as its continuing royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs for the foreseeable future.

Pipeline Programs and Near-term Milestones

• Respiratory Syncytial Virus (RSV): N-Protein Inhibitor EDP-938, Human Metapneumovirus (hMPV) and SARS-CoV-2
  • Continue with plans to broaden the RSVP study into the Southern Hemisphere, and to expand to trials sites in Europe and North America in the fall and winter RSV season, with the goal of having data in the third quarter of 2021
  • Plan to initiate Phase 2 dose ranging study in pediatric patients with RSV in 4Q 2020
  • Plan to initiate Phase 2 study in adult transplant patients with RSV in 4Q 2020
  • Perform optimization of Enanta’s current nanomolar hMPV inhibitor leads
  • Advance efforts for discovery of direct-acting antiviral compounds for SARS-CoV-2

• Hepatitis B (HBV): Core Inhibitor EDP-514
  • Initiate Phase 1b study in viremic HBV patients in 2Q 2020
  • Resume recruitment in Phase 1b study in nuc-suppressed HBV patients, currently paused

• Non-Alcoholic Steatohepatitis (NASH): Farnesoid X Receptor (FXR) Agonists EDP-305 and EDP-297
  • Resume recruitment and dosing in ARGON-2 Phase 2b study of EDP-305 in NASH, currently paused
  • Plan to initiate Phase 1 study of EDP-297 (follow-on FXR for NASH) in 3Q 2020
  • Advance efforts for discovery of non-FXR compounds for NASH

• Hepatitis C (HCV) Collaboration with AbbVie
  • AbbVie announced that the European Commission approved a change to the marketing authorization for MAVIRET® (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic HCV patients with genotype (GT) 3 infection. The decision makes MAVIRET the only pan-genotypic (GTs 1-6) 8-week treatment option for treatment-naïve, chronic HCV patients, without cirrhosis or with compensated cirrhosis.

Upcoming Events and Presentations

• May 19, 2020 – RBC Capital Markets Global Healthcare Conference, Virtual
• June 18, 2020 – Raymond James Healthcare Conference, Virtual
• Enanta plans to issue its fiscal third quarter financial results press release, and hold a conference call regarding those results, on August 4, 2020.

Conference Call and Webcast Information

Enanta will host a conference call and webcast today at 4:30 p.m. ET. To participate in the live conference call, please dial [phone] in the U.S. or [phone] for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on May 6, 2020, through 11:59 p.m. ET on May 8, 2020 by dialing [phone] from the U.S. or [phone] for international callers. The passcode for both the live call and the replay is 4261269. A live audio webcast of the call and replay can be accessed by visiting the “Events and Presentation” section on the “Investors” page of Enanta’s website at www.enanta.com.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV) and emerging coronaviruses, including SARS-CoV-2.

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta and now marketed by AbbVie as part of its leading treatment for chronic HCV infection, is sold under the brand names MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, including statements with respect to the prospects for advancement of Enanta’s clinical programs in RSV, NASH and HBV, as well as discovery programs in hMPV and SARS-CoV-2, and prospects for future royalty revenue from sales of AbbVie’s MAVYRET®/MAVIRET® HCV regimen. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta’s revenues in the short-term are dependent upon the level of AbbVie’s sales of its MAVYRET®/MAVIRET® HCV regimen; the impact of development, regulatory and marketing efforts of others with respect to competitive treatments for RSV, NASH, and HBV; competitive pricing, market acceptance and reimbursement rate actions affecting MAVYRET®/MAVIRET® compared to competitive HCV products on the market; the discovery and development risks of Enanta’s programs in RSV, NASH, HBV, hMPV, SARS-CoV-2; the competitive impact of development, regulatory and marketing efforts of others in those disease areas; Enanta’s lack of clinical development experience; Enanta’s need to attract and retain senior management and key research and development personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s most recent Form 10-Q for the quarter ended December 31, 2019, and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

ENANTA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED (in thousands, except per share amounts)
			Three Months Ended		Six Months Ended
			March 31,		March 31,
			2020	2019	2020	2019
Revenue			$ 27,619	$ 39,631	$ 80,189	$ 109,517
Operating expenses
	Research and development		32,610	34,155	65,388	69,033
	General and administrative		6,884	6,780	13,805	13,932
		Total operating expenses	39,494	40,935	79,193	82,965
Income (loss) from operations			(11,875)	(1,304)	996	26,552
Other income, net			1,950	2,245	4,026	4,130
Income (loss) before income taxes			(9,925)	941	5,022	30,682
Income tax (expense) benefit			3,920	3,204	2,416	(526)
Net income (loss)			$ (6,005)	$ 4,145	$ 7,438	$ 30,156
Net income (loss) per share
	Basic		$ (0.30)	$ 0.21	$ 0.37	$ 1.55
	Diluted		$ (0.30)	$ 0.20	$ 0.36	$ 1.44
Weighted average common shares outstanding
	Basic		19,922	19,549	19,836	19,487
	Diluted		19,922	21,084	20,692	20,946

ENANTA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED (in thousands)
			March 31,	September 30,
			2020	2019
Assets
Current assets
	Cash and cash equivalents		$                   74,338	$                    51,230
	Short-term marketable securities		280,917	284,006
	Accounts receivable		27,619	51,313
	Prepaid expenses and other current assets		19,835	15,299
		Total current assets	402,709	401,848
Long-term marketable securities			80,099	65,013
Property and equipment, net			9,738	10,927
Deferred tax assets			12,418	11,341
Operating lease, right-of-use assets			7,837	—
Restricted cash			608	608
Other long-term assets			92	92
		Total assets	$                  513,501	$                   489,829
Liabilities and Stockholders' Equity
Current liabilities
	Accounts payable		$                      5,945	$                       6,689
	Accrued expenses and other current liabilities		9,807	15,920
	Operating lease liabilities		3,764	—
		Total current liabilities	19,516	22,609
Operating lease liabilities, net of current portion			5,330	—
Series 1 nonconvertible preferred stock			1,628	1,628
Other long-term liabilities			1,036	3,100
		Total liabilities	27,510	27,337
Total stockholders' equity			485,991	462,492
		Total liabilities and stockholders' equity	$                  513,501	$                   489,829